2021年06月18日讯 / 生物谷 BIOON/ --赛诺菲（Sanofi）近日宣布，欧盟委员会（EC）已批准扩大Aubagio（teriflunomide，特立氟胺）适用人群，用于一线治疗年龄10-17岁的复发-缓解型多 …

Teriflunomide, sold under the brand name Aubagio, is the active metabolite of leflunomide. [6] Teriflunomide was investigated in the Phase III clinical trial TEMSO as a medication for …

AUBAGIO® (teriflunomide) is a prescription medication with a boxed warning. Refer to the Prescribing Information and Medication Guide for more details.

AUBAGIO® (teriflunomide) is a once-daily oral medication indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (MS ) to reduce the frequency of relapse 1

2024年8月5日 · Aubagio (teriflunomide) is used to reduce flare-ups in people with relapsing multiple sclerosis (MS). Includes Aubagio side effects, interactions and indications.

AUBAGIO® is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive …

2024年5月15日 · Aubagio is a brand (trade) name for teriflunomide and is used to treat relapsing forms of multiple sclerosis (MS) in adults. Experts aren't sure exactly how Aubagio works in …

2024年11月18日 · Aubagio ® is an immunomodulatory disease-modifying therapy that helps support the immune system. Relapsing forms of multiple sclerosis in adults, including clinically …

Indication: AUBAGIO is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (MS).

AUBAGIO is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS). DOSAGE AND ADMINISTRATION: The treatment should be initiated and supervised …